The FDA has granted fast track designation to Scholar Rock’s apitegromab (Isembyld), a muscle-targeting therapy recently approved for the treatment of spinal muscular atrophy (SMA), for patients ...
Xenon Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for azetukalner (XEN1101) as adjunctive treatment for focal seizures in adults with epilepsy, based on ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...
Foundational health behaviors reduce migraine burden, but frequent or disabling attacks commonly require preventive treatment ...
The 2026 AHA/ASA adult stroke rehabilitation guideline updates the 2016 framework, addressing evidence-based recovery ...
The FDA has approved UX111 (Fayuvi; Ultragenyx Pharmaceutical), an adeno-associated virus serotype 9 (AAV9) gene therapy, for the treatment of pediatric patients with Sanfilippo syndrome type A ...
HIMALAYA was a multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted at 63 sites across 13 ...
Levacetylleucine (AQNEURSA) is approved for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg, in addition to its existing indication for ...
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes] ...
"Unmet Needs and Mechanisms Behind Newer Agitation Therapies" takes up what still remains unmet in agitation care, and the biology behind a newer treatment option.
In early September, the FDA approved zilganersen injection (Zanvastro; Ionis) for the treatment of Alexander disease in pediatric and adult patients, marking the first approved th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results